Posted by Michael Wonder on 05 Nov 2018
CADTH publishes initial recommendation for Lenvima
5 November 2018 - CADTH has published its initial recommendation on the use of lenvatinib mesylate in combination with everolimus for the treatment of patients with advanced or metastatic, clear-cell renal cell carcinoma following one prior VEGF-targeted therapy.
The pERC Expert Review Committee does not recommend the use of lenvatinib mesylate in combination for the treatment of patients with advanced or metastatic, clear-cell renal cell carcinoma following one prior VEGF-targeted therapy.
The Committee is not convinced that there is a net clinical benefit for lenvatinib mesylate and everolimus when compared with everolimus monotherapy.
